Fast Five Quiz: Metastatic Melanoma

Adil Daud, MD


March 15, 2023

Immune checkpoint inhibitors have been shown to be effective regardless of BRAF mutation status. Subgroup analyses in CheckMate 067 and 069 have demonstrated improved efficacy with nivolumab-ipilimumab combination therapy compared with ipilimumab monotherapy, irrespective of BRAF mutation status, noted by both the NCCN and EDF guidelines.

BRAF inhibitors combined with MEK inhibitors have been shown to be superior to BRAF inhibitor monotherapy, both in terms of progression-free survival and overall survival, whereas toxicity is similar and controllable between the two.

Learn more about the treatment of metastatic melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.